Phase II non-randomized study combining yttrium 90 ibritumomab tiuxetan (Zevalin) with high-dose chemotherapy [BEAM: busulfan + etoposide + cyclophosphamide + melphalan] prior to autologous stem cell transplantation in patients with relapsed, refractory, or transformed non-Hodgkin's lymphoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carmustine; Cytarabine; Etoposide; Ibritumomab tiuxetan; Melphalan
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Apr 2007 New trial record.
- 27 Feb 2007 Biomarkers information updated